Filter Search for grants
Call Navigation
Call key data
Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
Funding Program
Horizon Europe: Cluster 1 - Health
Call number
HORIZON-HLTH-2026-01-CARE-01
deadlines
Opening
10.02.2026
Deadline
16.04.2026 17:00
Funding rate
50%
Call budget
€ 24,500,000.00
Estimated EU contribution per project
between € 3,000,000.00 and € 8,000,000.00
Link to the call
Link to the submission
Call content
short description
Public Procurement of Innovative Solutions (PPI) can boost the wider market uptake of high impact innovations in health systems, while enhancing the tools available to providers and improving access to healthcare for citizens. This supports enhancement of social rights and the European economic competitiveness by providing business opportunities and thus incentives to innovate. By acting as early adopters of innovative solutions, procurers can open up new growth markets for the European industry and small and medium-sized enterprises (SMEs). Joint/collaborative demand-driven initiatives can help create economies of scale and facilitate the wider adoption of innovations in the health sector for the benefits of patients in need.
Call objectives
PPI actions target consortia of procurers with a similar need that want to procure together the deployment of innovative solutions for supporting integration of care or diagnostics for personalised medicine. This topic does not provide direct funding to developers, industry or research organisations to perform research and development. They will be able to respond to the call for tenders launched by consortia of procurers funded under this topic.
Proposals should specify which segment of the patient population they target, the specific organisational and/or technological innovations to be procured, and why the proposed innovative solutions would be fit for purpose adhering, when relevant, to the principles of integrated care or personalised medicine.
Examples of target groups that could be covered by this action are: patients at risk of vulnerability such as children and older/frail people with complex needs for health and social care; people with multi-morbidities or non-communicable diseases of high burden; people with both physical and mental health conditions; people living with rare diseases or cancer; persons with disabilities; other groups of patients in need of highly integrated and coordinated care. Proposals should pay attention to how gender and intersectional factors (e.g. caregiving responsibilities, work-related health disparities etc.) affect healthcare access and outcomes.
Proposals should demonstrate, with qualitative and quantitative indicators, how they contribute to the above expected outcomes, clearly describe the application of the principles of integrated care and personalised medicine in the deployed solutions, when relevant. This would also include embedding the innovation in the existing health systems, addressing gaps and avoiding overlaps, while fostering change management across organisations, professions and sectors.
Solutions envisaged within this action are for example digital solutions, including Artificial Intelligence (AI) elements, to facilitate delivery of integrated care across hospitals, primary care, Long-Term Care (LTC) facilities and home settings, or technologies that improve routine diagnosis and lead to personalised medicine approach with the health and care setting.
The actions should target first deployment of innovative solutions across different health and care jurisdictions in Europe by engaging public and/or private procurers from each participating country (at national, regional or local level) that have deployment responsibilities and budget control in the provision of health and care services. Procurers will specify, purchase and deploy solutions addressing their relevant and shared unmet needs, while engaging together in a supply and demand side dialogue. Proposals should be based on clearly identified user needs and well-structured deployment plans, explaining how the procurement of the innovative solutions will contribute to the expected outcomes and improve current practice. In addition, cost-effectiveness analyses as well as estimates of the wider economic impact are highly desirable.
Activities covered should include cooperation with policymakers to reinforce national/regional policy frameworks and policies, to raise awareness, for technical assistance and/or capacity building beyond the project, to mainstream PPI implementation and remove obstacles to introduce innovative solutions to the market.
A wide variety of settings are potentially relevant for the implementation of such innovative solutions, for example primary healthcare settings, hospitals, specialised centres, long-term care facilities and home settings. The involvement of end-users (including for analysing the impact of the deployed solutions on health professionals and patients across the care continuum) and the use of cross-sectorial approaches are necessary. When relevant, linkage with ongoing work at national level for the implementation of the European Health Data Space (EHDS) is encouraged. Proposals are encouraged to consider, where relevant, the data, expertise and services offered by European research infrastructures in the health domain.
Transfer and adaptation of solutions and/or interventions from other sectors to healthcare is possible. The topic is open both to innovations bringing improvements mainly based on one specific solution/technology field, as well as to innovations delivering end-to-end solutions that need combinations of different types of innovative elements. Proposals are strongly encouraged to build upon past work and build synergies with ongoing EU-funded initiatives, for example the Joint Actions JADECARE and Xt-EHR, the project MyHealth@Myhands and the three co-funded European Partnerships on Transforming Health and Care Systems, on Personalised Medicine and on Rare Diseases, as well as with actions supported under the Technical Support Instrument and the Cohesion Policy Funds.
read more
Expected results
This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Ensuring equal access to innovative, sustainable, and high-quality healthcare”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to several of the following expected outcomes:
- Patients and their carers, health authorities and health professionals will benefit from the deployment of innovative solutions, designed around actual clinical needs, that facilitate identification, integration or coordination of care, allowing for personalised, more accessible, inclusive and higher quality of health and care.
- Patients will benefit from personalised approaches, improved care experiences and health outcomes or are more engaged in their care and better equipped to make informed decisions on their health, in collaboration with health professionals.
- Health professionals will be better equipped with, and thus benefit from, improved means for diagnosis, care delivery and/or coordination, with multi-disciplinary approaches and closer patient engagement, thanks to new technologies.
- Health systems will improve their accessibility, coordination mechanisms, effectiveness, inclusivity and resilience, thanks to innovative solutions, with a better use of resources, thus stimulating organisational innovation, cultural transformation within hospitals, and European-level collaboration.
read more
Eligibility Criteria
Regions / countries for funding
eligible entities
EU Body, Education and training institution, Non-Profit Organisation (NPO) / Non-Governmental Organisation (NGO), Other, Private institution, incl. private company (private for profit), Public Body (national, regional and local; incl. EGTCs), Research Institution incl. University, Small and medium-sized enterprise (SME)
Mandatory partnership
Yes
Project Partnership
To be eligible for funding, applicants must be established in one of the following countries:
- the Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden.
- the Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR).
- countries associated to Horizon Europe; Albania, Arab Republic of Egypt, Armenia, Bosnia and Herzegovina, Canada, Faroe Islands, Georgia, Iceland, Israel, Kosovo, Moldova, Montenegro, New Zealand, North Macedonia, Norway, Republic of Korea, Serbia, Switzerland, Tunisia, Türkiye, Ukraine, United Kingdom. Other third countries may become associated to Horizon Europe during the programme. For the purposes of the eligibility conditions, applicants established in other third countries negotiating association to Horizon Europe will be treated as entities established in an Associated Country, if the Horizon Europe association agreement with the third country concerned applies at the time of signature of the grant agreement.
- the following low- and middle-income countries: Afghanistan, Algeria, Angola, Argentina, Azerbaijan, Bangladesh, Belarus, Belize, Benin, Bhutan, Bolivia, Botswana, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Central African Republic, Chad, Colombia, Comoros, Congo (Democratic Republic), Congo (Republic), Costa Rica, Côte d'Ivoire, Cuba, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt (Arab Republic), El Salvador, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Fiji, Gabon, Gambia, Ghana, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Honduras, Indonesia, Iran (Islamic Republic), Iraq, Jamaica, Jordan, Kazakhstan, Kenya, Kiribati, Korea (Democratic People's Republic), Kyrgyz Republic, Lao (People’s Democratic Republic), Lebanon, Lesotho, Liberia, Libya, Madagascar, Malawi, Malaysia, Maldives, Mali, Marshall Islands, Mauritania, Mauritius, Micronesia (Federated States), Mongolia, Morocco, Mozambique, Myanmar, Namibia, Nepal, Nicaragua, Niger, Nigeria, Niue, Pakistan, Palau, Palestine, Papua New Guinea, Paraguay, Peru, Philippines, Rwanda, Samoa, São Tomé and Principe, Senegal, Sierra Leone, Solomon Islands, Somalia, South Africa, South Sudan, Sri Lanka, St. Lucia, St. Vincent and the Grenadines, Sudan, Suriname, Syrian Arab Republic, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Turkmenistan, Tuvalu, Uganda, Uzbekistan, Vanuatu, Venezuela (Bolivarian Republic), Vietnam, Yemen Republic, Zambia, Zimbabwe.
- In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call/topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
Any legal entity, regardless of its place of establishment, including legal entities from non associated third countries or international organisations (including international European research organisations) is eligible to participate (whether it is eligible for funding or not), provided that the conditions laid down in the Horizon Europe Regulation have been met, along with any other conditions laid down in the specific call/topic.
A ‘legal entity’ means any natural or legal person created and recognised as such under national law, EU law or international law, which has legal personality and which may, acting in its own name, exercise rights and be subject to obligations, or an entity without legal personality.
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows:
- at least one independent legal entity established in a Member State; and
- at least two other independent legal entities, each established in different Member States or Associated Countries.
As affiliated entities do not sign the grant agreement, they do not count towards the minimum eligibility criteria for consortium composition (if any).
In recognition of the opening of the US National Institutes of Health’s programmes to European researchers, any legal entity established in the United States of America is eligible to receive Union funding.
If projects use satellite-based earth observation, positioning, navigation and/or related timing data and services, beneficiaries must make use of Copernicus and/or Galileo/EGNOS (other data and services may additionally be used).
Subject to restrictions for the protection of European communication networks.
other eligibility criteria
Specific cases
Affiliated entities — Affiliated entities (i.e. entities with a legal or capital link to a beneficiary which participate in the action with similar rights and obligations to the beneficiaries, but which do not sign the grant agreement and therefore do not become beneficiaries themselves) are allowed, if they are eligible for participation and funding.
Associated partners — Associated partners (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any specific call/topic conditions.
Entities without legal personality — Entities which do not have legal personality under their national law may exceptionally participate, provided that their representatives have the capacity to undertake legal obligations on their behalf, and offer guarantees to protect the EU’s financial interests equivalent to those offered by legal persons.
EU bodies — Legal entities created under EU law including decentralised agencies may be part of the consortium, unless provided for otherwise in their basic act.
International organisations — International European research organisations are eligible to receive funding. International organisations with headquarters in a Member State or Associated Country are eligible to receive funding for ‘Training and mobility’ actions or when provided for in the specific call/topic conditions. Other international organisations are not eligible to receive funding, unless provided for in the specific call/topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
Joint Research Centre (‘JRC’) — Where provided for in the specific call/topic conditions, applicants may include in their proposals the possible contribution of the JRC, but the JRC will not participate in the preparation and submission of the proposal. Applicants will indicate the contribution that the JRC could bring to the project based on the scope of the topic text. After the evaluation process, the JRC and the consortium selected for funding may come to an agreement on the specific terms of the participation of the JRC. If an agreement is found, the JRC may accede to the grant agreement as beneficiary requesting zero funding or participate as an associated partner, and would accede to the consortium as a member.
Associations and interest groupings — Entities composed of members (e.g. European research infrastructure consortia (ERICs)) may participate as ‘sole beneficiaries’ or ‘beneficiaries without legal personality’. However, if the action is in practice implemented by the individual members, those members should also participate either as beneficiaries or as affiliated entities (otherwise their costs will NOT be eligible).
EU restrictive measures — Entities subject to EU restrictive measures under Article 29 of the Treaty on the European Union (TEU) and Article 215 of the Treaty on the Functioning of the EU (TFEU) as well as Article 75 TFEU, are not eligible to participate in any capacity, including as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any).
Legal entities established in Russia, Belarus, or in non-government controlled territories of Ukraine — Given the illegal invasion of Ukraine by Russia and the involvement of Belarus, there is currently no appropriate context allowing the implementation of the actions foreseen in this programme with legal entities established in Russia, Belarus, or in non-government controlled territories of Ukraine. Therefore, even where such entities are not subject to EU restrictive measures, such legal entities are not eligible to participate in any capacity. This includes participation as beneficiaries, affiliated entities, associated partners, third parties giving in-kind contributions, subcontractors or recipients of financial support to third parties (if any). Exceptions may be granted on a case-by-case basis for justified reasons.
With specific regard to measures addressed to Russia, following the adoption of the Council Regulation (EU) 2024/1745 of 24 June 2024 (amending Council Regulation (EU) No 833/2014 of 31 July 2014) concerning restrictive measures in view of Russia’s actions destabilising the situation in Ukraine, legal entities established outside Russia whose proprietary rights are directly or indirectly owned for more than 50% by a legal person, entity or body established in Russia are also not eligible to participate in any capacity.
Measures for the protection of the Union budget against breaches of the principles of the rule of law in Hungary — Following the Council Implementing Decision (EU) 2022/2506, as of 16 December 2022, no legal commitments can be entered into with Hungarian public interest trusts established under the Hungarian Act IX of 2021 or any entity they maintain. Affected entities may continue to apply to calls for proposals and can participate without receiving EU funding, as associated partners, if allowed by the call conditions. However, as long as the Council measures are not lifted, such entities are not eligible to participate in any funded role (beneficiaries, affiliated entities, subcontractors, recipients of financial support to third parties, etc.). In the case of multi-beneficiary grant calls, applicants will be invited to remove or replace that entity in any funded role and/or to change its status into associated partner. Tasks and budget may be redistributed accordingly.
Additional information
Topics
Relevance for EU Macro-Region
EUSDR - EU Strategy for the Danube Region, EUSBSR - EU Strategy for the Baltic Sea Region, EUSALP - EU Strategy for the Alpine Space, EUSAIR - EU Strategy for the Adriatic and Ionian Region
UN Sustainable Development Goals (UN-SDGs)
Additional Information
Applications must be submitted electronically via the Funders & Tenders Portal electronic submission system (accessible via the topic page in the Search Funding & Tenders section). Paper submissions are NOT possible.
Applications must be submitted using the forms provided inside the electronic submission system (not the templates available on the topic page, which are only for information). The structure and presentation must correspond to the instructions given in the forms.
Applications must be complete and contain all parts and mandatory annexes and supporting documents.
Applications must include a plan for the exploitation and dissemination of results including communication activities, unless provided otherwise in the specific call/topic conditions. The plan is not required for applications at the first stage of two-stage procedures. If the expected exploitation of the results entails developing, creating, manufacturing and marketing a product or process, or in creating and providing a service, the plan must include a strategy for such exploitation. If the plan provides for exploitation of the results primarily in non-associated third countries, the applicants must explain how that exploitation is to be considered in the EU’s interest.
The application form will have two parts:
- Part A (to be filled in directly online) contains administrative information about the applicant organisations (future coordinator and beneficiaries and affiliated entities), the summarised budget for the proposal and call-specific questions;
- Part B (to be downloaded from the Portal submission system, completed and then assembled and re-uploaded as a PDF in the system) contains the technical description of the project.
Annexes and supporting documents will be directly available in the submission system and must be uploaded as PDF files (or other formats allowed by the system).
The limit for a full application (Part B) is 40 pages.
The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.
Beneficiaries may provide financial support to third parties to ensure the deployment and impact of the project outcomes. The support to third parties can only be provided in the form of grants. The maximum amount to be granted to each third party is EUR 60 000.
The specific conditions for actions with PCP/PPI procurements in section H of the General Annexes apply to grants funded under this topic.
PPI procurement costs are eligible.
Call documents
Horizon Europe Work Programme 2026-2027 Cluster 1 - HealthHorizon Europe Work Programme 2026-2027 Cluster 1 - Health(1700kB)
Contact
To see more information about this call, you can register for free here
or log in with an existing account.
Log in
Register now

